- From ADOLOR to ▇▇▇▇▇▇▇. (a) Should ADOLOR establish the therapeutic index of the Compound but nonetheless decline to initiate Phase B, ADOLOR shall deliver to ▇▇▇▇▇▇▇ copies of ADOLOR data on the therapeutic index of the Compound and any other ADOLOR data on the therapeutic efficacy of the Compound as well as any dosage forms containing the Compound. (b) Should ADOLOR fail to establish the therapeutic index and should ADOLOR not dispute that the term of Phase A, taking into consideration any extensions thereto under Section 3.2, has expired, then ADOLOR shall deliver to ▇▇▇▇▇▇▇ copies of ADOLOR data on the therapeutic index of the Compound and any *Confidential Treatment Requested. Omitted portions filed with the Securities and Exchange Commission (the “Commission”). other ADOLOR data on the therapeutic efficacy of the Compound as well as any dosage forms containing the Compound.
Appears in 1 contract
Sources: Option and License Agreement (Cubist Pharmaceuticals Inc)
- From ADOLOR to ▇▇▇▇▇▇▇. (a) Should ADOLOR establish the therapeutic index of the Compound but nonetheless decline to initiate Phase B, ADOLOR shall deliver to ▇▇▇▇▇▇▇ copies of ADOLOR data on the therapeutic index of the Compound and any other ADOLOR data on the therapeutic efficacy of the Compound as well as any dosage forms containing the Compound.
(b) Should ADOLOR fail to establish the therapeutic index and should ADOLOR not dispute that the term of Phase A, taking into consideration any extensions thereto under Section 3.2, has expired, then ADOLOR shall deliver to ▇▇▇▇▇▇▇ copies of ADOLOR data on the therapeutic index of the Compound and any *Confidential Treatment Requested. Omitted portions filed with the Securities and Exchange Commission (the “Commission”). other ADOLOR data on the therapeutic efficacy of the Compound as well as any dosage forms containing the Compound.
Appears in 1 contract
- From ADOLOR to ▇▇▇▇▇▇▇. (a) Should ADOLOR establish the therapeutic index of the Compound but nonetheless decline to initiate Phase B, ADOLOR shall deliver to ▇▇▇▇▇▇▇ copies of ADOLOR data on the therapeutic index of the Compound and any other ADOLOR data on the therapeutic efficacy of the Compound as well as any dosage forms containing the Compound.
(b) Should ADOLOR fail to establish the therapeutic index and should ADOLOR not dispute that the term of Phase A, taking into consideration any extensions thereto under Section 3.2, has expired, then ADOLOR shall deliver to ▇▇▇▇▇▇▇ copies of ADOLOR data on the therapeutic index of the Compound and any *Confidential Treatment Requested. Omitted portions filed with the Securities and Exchange Commission (the “Commission”). other ADOLOR data on the therapeutic efficacy of the Compound as well as any dosage forms containing the Compound.
(c) All such materials delivered to ▇▇▇▇▇▇▇ pursuant to this Section 6.2 shall thus become the sole and exclusive property of ▇▇▇▇▇▇▇.
Appears in 1 contract